From Deciphex on LinkedIn: Last week, Deciphex had the privilege of joining a dynamic AI panel hosted by Novartis Ireland , alongside industry leaders and policymakers, to discuss the future of AI in pathology and Ireland’s role as a...

From Deciphex on LinkedIn: 🚨 Don’t Miss Our Upcoming Webinar! 🚨 Join us for the second webinar in our series with Charles River Laboratories, where we’ll reveal the results of a time and motion study on Patholytix Foresight!...

From Deciphex on LinkedIn: We’re excited to announce that Gary Roche, our Business Development Manager, will be attending the 14th Global Summit on Regulatory Science, hosted by the FDA in Little Rock, Arkansas. Gary will be there to...

With Patholytix 3.0, Deciphex overcomes one of the last barriers to full-scale adoption of digital pathology. For the first time, users can review and score non-clinical studies on a single platform. The benefit is faster pathology reviews,...

DUBLIN, Ireland, May 19th 2022— Deciphex, a leading provider of pathology software and services, announced today the closing of a $11.5 million Series B funding round. The round was led by ACT Venture Capital, with Charles River...

        WILMINGTON, MA and DUBLIN, Ireland March 30 2020 -- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a partnership with Deciphex, a leader in...